Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Operating Expenses: 2009-2024

Historic Operating Expenses for Ligand Pharmaceuticals (LGND) over the last 16 years, with Dec 2024 value amounting to $189.7 million.

  • Ligand Pharmaceuticals' Operating Expenses rose 24.37% to $60.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $233.7 million, marking a year-over-year increase of 38.50%. This contributed to the annual value of $189.7 million for FY2024, which is 56.17% up from last year.
  • According to the latest figures from FY2024, Ligand Pharmaceuticals' Operating Expenses is $189.7 million, which was up 56.17% from $121.5 million recorded in FY2023.
  • Over the past 5 years, Ligand Pharmaceuticals' Operating Expenses peaked at $193.2 million during FY2022, and registered a low of $121.5 million during FY2023.
  • Over the past 3 years, Ligand Pharmaceuticals' median Operating Expenses value was $189.7 million (recorded in 2024), while the average stood at $168.1 million.
  • Per our database at Business Quant, Ligand Pharmaceuticals' Operating Expenses slumped by 37.12% in 2023 and then skyrocketed by 56.17% in 2024.
  • Ligand Pharmaceuticals' Operating Expenses (Yearly) stood at $143.2 million in 2020, then declined by 3.83% to $137.7 million in 2021, then surged by 40.32% to $193.2 million in 2022, then tumbled by 37.12% to $121.5 million in 2023, then spiked by 56.17% to $189.7 million in 2024.